Therefore, the search for potential therapeutic drugs that target AKT and/or UPR pathways appears as a promising strategy in the fight against COVID-19, particularly for patients with comorbidities such as cancer, obesity and/or diabetes. Here, AKT1 is linked to obesity due to melanocortin 4 receptor deficiency.